dc.contributor.author |
Homaidan F.R. |
dc.contributor.editor |
|
dc.date |
2005 |
dc.date.accessioned |
2017-09-07T07:00:04Z |
dc.date.available |
2017-09-07T07:00:04Z |
dc.date.issued |
2005 |
dc.identifier |
10.2174/1568014054065294 |
dc.identifier.isbn |
|
dc.identifier.issn |
15680142 |
dc.identifier.uri |
http://hdl.handle.net/10938/11253 |
dc.description.abstract |
[No abstract available] |
dc.format.extent |
|
dc.language |
English |
dc.relation.ispartof |
Publication Name: Current Medicinal Chemistry: Anti-Inflammatory and Anti-Allergy Agents; Publication Year: 2005; Volume: 4; no. 3; Pages: (281 |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Editorial |
dc.type |
Editorial |
dc.contributor.affiliation |
Homaidan, F.R., Department of Physiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon |
dc.contributor.authorAddress |
Homaidan, F.R.; Department of Physiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon; email: fh01@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Anatomy, Cell Biology and Physiological Sciences; |
dc.contributor.authorDepartment |
Anatomy, Cell Biology and Physiological Sciences |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
|
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
|
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
|
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
|
dc.description.citedCount |
|
dc.description.citedTotWOSCount |
|
dc.description.citedWOSCount |
|
dc.format.extentCount |
-280 |
dc.identifier.articleNo |
|
dc.identifier.coden |
CMCAG |
dc.identifier.pubmedID |
|
dc.identifier.scopusID |
22444431766 |
dc.identifier.url |
|
dc.publisher.address |
|
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
|
dc.relation.ispartOfIssue |
3 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Current Medicinal Chemistry: Anti-Inflammatory and Anti-Allergy Agents |
dc.relation.ispartofPubTitleAbbr |
Curr. Med. Chem.: Anti-Inflammatory Anti-Allergy Agents |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
4 |
dc.source.ID |
|
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
|
dc.subject.otherChemCAS |
prostacyclin, 35121-78-9, 61849-14-7 |
dc.subject.otherChemCAS |
prostaglandin E2, 363-24-6 |
dc.subject.otherChemCAS |
thymulin, 78922-62-0 |
dc.subject.otherIndex |
antiinflammatory agent |
dc.subject.otherIndex |
cell adhesion molecule |
dc.subject.otherIndex |
fatty acid |
dc.subject.otherIndex |
I kappa B |
dc.subject.otherIndex |
icosanoid |
dc.subject.otherIndex |
immunoglobulin enhancer binding protein |
dc.subject.otherIndex |
interleukin 1 |
dc.subject.otherIndex |
interleukin 12 receptor inhibitor |
dc.subject.otherIndex |
interleukin 6 |
dc.subject.otherIndex |
leukotriene |
dc.subject.otherIndex |
prostacyclin |
dc.subject.otherIndex |
prostaglandin |
dc.subject.otherIndex |
prostaglandin E2 |
dc.subject.otherIndex |
thymulin |
dc.subject.otherIndex |
tumor necrosis factor alpha |
dc.subject.otherIndex |
tumor necrosis factor antagonist |
dc.subject.otherIndex |
unclassified drug |
dc.subject.otherIndex |
allergy |
dc.subject.otherIndex |
arthritis |
dc.subject.otherIndex |
asthma |
dc.subject.otherIndex |
atherosclerosis |
dc.subject.otherIndex |
atherosclerotic plaque |
dc.subject.otherIndex |
autoimmune disease |
dc.subject.otherIndex |
Behcet disease |
dc.subject.otherIndex |
blood vessel permeability |
dc.subject.otherIndex |
blood vessel tone |
dc.subject.otherIndex |
cardiovascular disease |
dc.subject.otherIndex |
clinical feature |
dc.subject.otherIndex |
coronary artery disease |
dc.subject.otherIndex |
drug efficacy |
dc.subject.otherIndex |
drug mechanism |
dc.subject.otherIndex |
drug targeting |
dc.subject.otherIndex |
editorial |
dc.subject.otherIndex |
enteritis |
dc.subject.otherIndex |
gastrointestinal disease |
dc.subject.otherIndex |
gene activation |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
hyperalgesia |
dc.subject.otherIndex |
inflammatory disease |
dc.subject.otherIndex |
lymphocyte transfer |
dc.subject.otherIndex |
microvasculature |
dc.subject.otherIndex |
molecular mechanics |
dc.subject.otherIndex |
neuromuscular disease |
dc.subject.otherIndex |
pathogenesis |
dc.subject.otherIndex |
protein expression |
dc.subject.otherIndex |
protein function |
dc.subject.otherIndex |
protein secretion |
dc.subject.otherIndex |
protein synthesis |
dc.subject.otherIndex |
protein targeting |
dc.subject.otherIndex |
rheumatoid arthritis |
dc.subject.otherIndex |
signal transduction |
dc.subject.otherIndex |
vasodilatation |
dc.subject.otherKeywordPlus |
|
dc.subject.otherWOS |
|